![]() |
Name |
7-Methyl-Z-tetradecen-1-ol acetate
|
Molecular Formula | C17H32O2 | |
IUPAC Name* |
[(Z)-7-methyltetradec-8-enyl] acetate
|
|
SMILES |
CCCCC/C=C\C(C)CCCCCCOC(=O)C
|
|
InChI |
InChI=1S/C17H32O2/c1-4-5-6-7-10-13-16(2)14-11-8-9-12-15-19-17(3)18/h10,13,16H,4-9,11-12,14-15H2,1-3H3/b13-10-
|
|
InChIKey |
IUOFQMYQDUARQU-RAXLEYEMSA-N
|
|
Synonyms |
7-Methyl-Z-tetradecen-1-ol acetate; (Z)-7-Methyltetradec-8-en-1-yl acetate; 959269-58-0; [(Z)-7-methyltetradec-8-enyl] acetate; starbld0009085; CHEBI:131377; (8Z)-7-Methyl-8-tetradecenyl acetate #; (8Z)-7-methyl-8-tetradecen-1-yl acetate; (8Z)-7-methyltetradec-8-en-1-yl acetate
|
|
CAS | NA | |
PubChem CID | 5363222 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 268.4 | ALogp: | 6.2 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 19 | QED Weighted: | 0.264 |
Caco-2 Permeability: | -4.677 | MDCK Permeability: | 0.00002620 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.997 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.806 | Plasma Protein Binding (PPB): | 95.60% |
Volume Distribution (VD): | 1.963 | Fu: | 4.86% |
CYP1A2-inhibitor: | 0.822 | CYP1A2-substrate: | 0.427 |
CYP2C19-inhibitor: | 0.541 | CYP2C19-substrate: | 0.239 |
CYP2C9-inhibitor: | 0.396 | CYP2C9-substrate: | 0.798 |
CYP2D6-inhibitor: | 0.279 | CYP2D6-substrate: | 0.304 |
CYP3A4-inhibitor: | 0.659 | CYP3A4-substrate: | 0.18 |
Clearance (CL): | 3.554 | Half-life (T1/2): | 0.688 |
hERG Blockers: | 0.154 | Human Hepatotoxicity (H-HT): | 0.061 |
Drug-inuced Liver Injury (DILI): | 0.348 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.053 | Maximum Recommended Daily Dose: | 0.016 |
Skin Sensitization: | 0.941 | Carcinogencity: | 0.089 |
Eye Corrosion: | 0.647 | Eye Irritation: | 0.964 |
Respiratory Toxicity: | 0.412 |